Johannes Beeslaar

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

Peter Richmond, Helen Marshall, Michael D. Nissen et al. · The Lancet Infectious Diseases · 2012 · 130 citations

Vaccination, Vaccine Safety, Healthy Adolescents +6

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

Lars Østergaard, Timo Vesikari, Judith Absalon et al. · New England Journal of Medicine · 2017 · 69 citations · Full text

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

Timo Vesikari, Lars Østergaard, Javier Díez‐Domingo et al. · Journal of the Pediatric Infectious Diseases Society · 2015 · 58 citations · Full text

Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents

Timo Vesikari, Jacek Wysocki, Johannes Beeslaar et al. · Journal of the Pediatric Infectious Diseases Society · 2016 · 42 citations · Full text

Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial

Helen Marshall, Peter Richmond, Johannes Beeslaar et al. · The Lancet Infectious Diseases · 2016 · 39 citations · Full text